重组人干扰素联合薄芝糖肽治疗高甲胎蛋白慢性乙型肝炎的临床观察  

Clinical Observation on Recombinant Human Interferon Combined with Bozhi Glycopeptides in Treatment of Hepatitis with High Alpha-fetoprotein

作　　者：张俊霞[1] 张丹[1] 李丽芳[1] 孔洪彬 赵斗贵[1] 

机构地区：[1]邯郸市传染病医院,河北邯郸056000

出　　处：《中国药房》2015年第9期1173-1175,共3页China Pharmacy

摘　　要：目的:观察重组人干扰素联合薄芝糖肽治疗高甲胎蛋白(AFP)慢性乙型肝炎的疗效及安全性。方法:选择我院82例高AFP慢性乙型肝炎患者,随机均分为观察组和对照组。观察组患者采用重组人干扰素α-2b注射液300万U肌肉注射、每日1次,连用4周后改为500万U、隔日1次;并以薄芝糖肽4 ml加入5%葡萄糖注射液200 ml中静脉滴注,每日1次。对照组患者仅采用重组人干扰素α-2b注射液治疗,用法用量同观察组。两组疗程均为16周。比较两组患者治疗前后丙氨酸氨基转移酶(ALT)、乙型肝炎e抗原(HBe Ag)、乙型肝炎病毒脱氧核糖核酸(HBV-DNA)拷贝数和AFP的变化,并观察不良反应发生情况。结果:治疗后,观察组患者ALT复常率和HBe Ag转阴率均显著高于对照组,差异有统计学意义(P<0.05);两组患者HBV-DNA拷贝数和AFP水平均显著低于本组治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组患者不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:重组人干扰素联合薄芝糖肽治疗高AFP慢性乙型肝炎较单用重组人干扰素疗效更好,可有效改善肝功能、抑制病毒增殖,且安全性较好。OBJECTIVE：To observe the clinical efficacy and safety of recombinant human interferon combined with Bozhi glycopeptides in the treatment of hepatitis with high alpha-fetoprotein（AFP）. METHODS：82 hepatitis patients with high AFP were randomly divided into observation group and control group. Observation group was given intramuscular injection with recombinant human interferon α-2b injection 3 million U,once a day;after 4 weeks,it changed to 5 million U,once every other day. And it was also treated with intravenous injection of Bozhi glycopeptides 4 ml in 5% glucose injection 200 ml,once a day. Control group was only given recombinant human interferon α-2b injection with the same dosage as observation group. The course was 16 weeks.The clinic data was compared before and after treatment,including the changes of alanine aminotransferase（ALT）,hepatitis B virus e antigen（HBe Ag）,hepatitis B virus DNA（HBV-DNA）copy number and AFP,and adverse reactions. RESULTS：After treatment,the normalization rate of ALT and negative conversion rate of HBe Ag in observation group were significantly higher than control group,with significant difference（P〈0.05）. The HBV-DNA copy number and AFP level in 2 groups were significantly lower than before,and observation group was lower than control group,with significant difference（P〈0.05）. The incidence of adverse reactions in observation group was significantly lower than control group,with significant difference（P〈0.05）. CONCLUSIONS：Recombinant human interferon combined with Bozhi glycopeptides has better efficacy than only recombinant human interferon in the treatment of hepatitis with high AFP level. It can effectively improve liver function and inhibit viral propagation with better safety.

关 键 词：慢性乙型肝炎 甲胎蛋白 重组人干扰素 薄芝糖肽 

分 类 号：R512.62[医药卫生—内科学]